78 results
8-K
EX-99.1
IMVT
Immunovant Inc
29 May 24
Results of Operations and Financial Condition
4:17pm
environment, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its clinical
8-K
EX-99.1
IMVT
Immunovant Inc
12 Feb 24
Results of Operations and Financial Condition
7:02am
-COVID-19 environment, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its
8-K
EX-99.1
IMVT
Immunovant Inc
9 Jan 24
Regulation FD Disclosure
8:08am
such as the post-COVID-19 environment, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chains
8-K
EX-99.1
7g1dhmcyll
20 Dec 23
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
4:37pm
8-K
EX-99.1
vo5i4w09r5bskckspf
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
8-K
EX-99.2
geifn
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
S-3ASR
EX-1.2
77qn7
9 Nov 23
Automatic shelf registration
8:49am
S-3ASR
7sxtwo0ww f8wt9i
9 Nov 23
Automatic shelf registration
8:49am
8-K
EX-99.1
eytvd
9 Nov 23
Results of Operations and Financial Condition
7:06am
424B5
exrox29wjhpnw0pa
29 Sep 23
Prospectus supplement for primary offering
4:48pm
8-K
EX-1.1
q6acysp lzlh
28 Sep 23
Entry into a Material Definitive Agreement
5:23pm
424B5
azta6di4s5j1t5
26 Sep 23
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
6fzow9i
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
8-K
EX-99.1
k68v1hg
10 Aug 23
Results of Operations and Financial Condition
7:10am